New insider activity at Janux Therapeutics Inc ( (JANX) ) has taken place on March 8, 2025.
Ra Capital Management, LLC, a former 10% owner, has made a significant investment in Janux Therapeutics Inc by purchasing 824,041 shares. This transaction is valued at $25,342,964, highlighting a strong vote of confidence in the company’s future prospects.
Recent Updates on JANX stock
In the last 24 hours, Janux Therapeutics Inc. has experienced notable developments impacting its stock. The company reported promising Phase 1 clinical trial data for its lead candidate, JANX007, showing high response rates in prostate cancer patients. Despite this, Scotiabank lowered its price target due to concerns that not all benchmarks for a competitive edge and potential acquisition have been met. Conversely, Wedbush raised its price target slightly, maintaining an optimistic outlook based on Janux’s continued patient enrollment and robust financial position. These mixed analyst reactions reflect differing views on the company’s strategic progress and future potential.
More about Janux Therapeutics Inc
YTD Price Performance: -42.24%
Average Trading Volume: 991,592
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.86B